Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AHCO vs AXGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AXGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–5 Matrix Metrics)
AXGN Overall Winner
6-Pillar Tally: AHCO 1 – 5 AXGN
Matrix Metrics: AHCO 5 – 4 AXGN
As of Nov 20, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas AXGN carries 35.7/100 (SELL) at $55.75 (79.0x Forward P/E, -5.2% operating margin).
- Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. AXGN 35.7/100 SELL), AXGN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 3.8% operating margin) and revenue trajectory (+26.2% vs. +10.9% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About AHCO vs AXGN
AHCO
AdaptHealth Corp. Common Stock
$7.20
-0.69% 1D
Market Cap
$989.8M
TTM Revenue
$3.44B
Forward P/E
7.8x
Beta / 30D Vol
0.17β · 67% Vol
Unified Composite Score
45.2
HOLD
Tech 29.0
Fund 46.0
Flow 54.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
AXGN
Head-to-Head Winner
Axogen, Inc. Common Stock
$55.75
-1.06% 1D
Market Cap
$3.4B
TTM Revenue
$267M
Forward P/E
79.0x
Beta / 30D Vol
1.22β · 121% Vol
Unified Composite Score
35.7
SELL
Tech 50.0
Fund 30.0
Flow 64.0
Mom 31.6
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (AHCO 1 – 5 AXGN)
1. Valuation Multiples
AHCO
Forward P/E
7.8x
79.0x
Trailing P/E
7.8x
125.0x
PEG Ratio
N/M
N/M
EV / Revenue
0.9x
11.5x
2. Growth & Scale
AXGN
Revenue Growth (YoY)
+10.9%
+26.2%
Earnings Growth (YoY)
+6.7%
+300.0%
TTM Revenue (USD)
$3.44B
$267M
Market Cap
$989.8M
$3.4B
3. Profitability & Quality
AXGN
Gross Margin
18.2%
74.2%
Operating Margin
3.8%
-5.2%
Net Profit Margin
-11.8%
-12.0%
Return on Equity (ROE)
-28.4%
-10.3%
4. Balance Sheet & Cash Flow
AXGN
Cash Generation (TTM)
$82M
$20M
Cash Flow Margin
2.4%
7.5%
Net Cash / Leverage
$1.97B Net Debt (1.67x D/E)
$309M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AXGN
Options Structure Phase
SURGE
SURGE
Current IV / %ile
66.9% (12th %ile)
72.6% (17th %ile)
Put/Call OI Skew
N/A
0.10x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
AXGN
OpEx & R&D Intensity
14.4% of Rev ($495M)
79.4% of Rev ($212M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AHCO (5) vs AXGN (4)| Institutional Metric | AHCO | AXGN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $989.8M | $3.4B | AXGN | |
| Trailing P/E Ratio | 7.8x | 125.0x | AHCO | |
| Forward P/E Ratio | 7.8x | 79.0x | AHCO | |
| Revenue Growth (YoY) | +10.9% | +26.2% | AXGN | |
| Operating Margin (TTM) | 3.8% | -5.2% | AHCO | |
| Net Profit Margin | -11.8% | -12.0% | Tie | |
| Return on Equity (ROE) | -28.4% | -10.3% | AXGN | |
| 52-Week Range Position | 24% ($5–$13) | 89% ($24–$60) | AXGN | |
| Beta / 30D Volatility | 0.17β · 67% Vol | 1.22β · 121% Vol | AHCO | |
| Unified Institutional Score | 45.2 / 100 (HOLD) | 35.7 / 100 (SELL) | AHCO | |
| Trailing 12M Revenue (USD) | $3.44B | $267M | Scale | |
| Gross Profit Margin (TTM) | 18.2% | 74.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.9x EV/Rev | N/M PEG · 11.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $82M ($1.97B Net Debt (1.67x D/E)) | $20M ($309M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AXGN +35.3 pp
3M Horizon
AHCO +14.65 pp
6M Horizon
AXGN +67.41 pp
1Y Horizon
AXGN +141.58 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AHCO Revenue | AXGN Revenue | AHCO Op. Margin | AXGN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $350M | $80M | 9.0% | -24.4% | AHCO |
| FY2019 | $530M | $110M | 5.5% | -29.4% | AHCO |
| FY2020 | $1.06B | $110M | 6.8% | -20.6% | AHCO |
| FY2021 | $2.45B | $130M | 9.2% | -20.0% | AHCO |
| FY2022 | $2.97B | $140M | 6.4% | -21.4% | AHCO |
| FY2023 | $3.20B | $160M | -18.7% | -13.5% | AXGN |
| FY2024 | $3.26B | $190M | 8.1% | -1.8% | AHCO |
| FY2025 | $3.24B | $230M | 2.8% | -3.5% | AHCO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
AHCO
SURGE
Current IV
66.9%
IV Percentile
12th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
AXGN
SURGE
Current IV
72.6%
IV Percentile
17th %ile
Put/Call OI Skew
0.10x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AXGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
AHCO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
14.4% of Rev ($495M)
90D Engineering Disclosures
0 Published
AXGN Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
79.4% of Rev ($212M)
90D Engineering Disclosures
0 Published
Investor FAQ AHCO vs AXGN Key Questions & Quantitative Answers
As of Nov 20, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas AXGN carries 35.7/100 (SELL) at $55.75 (79.0x Forward P/E, -5.2% operating margin). Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. AXGN 35.7/100 SELL), AXGN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 3.8% operating margin) and revenue trajectory (+26.2% vs. +10.9% YoY).
AXGN leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with AXGN at +26.2% YoY revenue growth and +300.0% YoY earnings growth on $267M TTM revenue (74.2% gross margin, -5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while AXGN shifted +187.5%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 79.4% of Rev ($212M) (0 disclosures) for AXGN.
AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas AXGN trades at 79.0x Forward P/E, 125.0x Trailing P/E, N/M PEG, and 11.5x EV/Revenue (7.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus AXGN (-10.3% ROE) capital efficiency.
In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, AXGN carries 72.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.22β · 121% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
AXGN vs AHCO · Reverse Pair
AHCO vs OPCH
· Sector Peer
AHCO vs ADUS
· Sector Peer
AHCO vs RPAY
· Sector Peer
AXGN vs ATRC
· Sector Peer
AXGN vs ANAB
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem